ADILADIAL PHARMACEUTICALS, INC.同业对比
ADIAL PHARMACEUTICALS, INC. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADIL本股 | $6M#14 | — | 1.6x#3 | — | — | 39.6%#4 | — | -214.6%#10 | — | — | -64.4%#13 | — |
| AAPG | $6.9B#4 | — | — | — | — | — | — | — | — | — | -55.3%#11 | — |
| AARD | $109M#11 | — | 1.3x#2 | — | — | -179.7%#10 | — | -66.2%#7 | — | — | -61.2%#12 | — |
| ABBV | $441.3B#1 | 123.1x#5 | — | 7.2x#3 | 8.6%#5 | -1.2%#7 | 24.6%#1 | — | 20.0%#1 | — | 34.6%#5 | — |
| ABCL | $2.2B#6 | — | 2.4x#4 | 29.6x#4 | 160.6%#1 | 10.1%#5 | -289.0%#5 | -15.6%#4 | -25.2%#4 | — | 72.5%#3 | — |
| ABEO | $406M#9 | 7.5x#2 | 2.8x#5 | 69.7x#5 | — | -211.7%#11 | -1536.9%#7 | -49.1%#6 | -101.1%#7 | — | 22.3%#8 | — |
| ABT | $164.3B#2 | 26.4x#4 | 3.2x#6 | 3.7x#1 | 5.7%#6 | -51.3%#8 | 18.2%#2 | 12.5%#2 | 8.3%#3 | — | -27.4%#10 | 2.5%#1 |
| ABUS | $1.0B#7 | 6.2x#1 | 3.9x#9 | 72.1x#6 | 128.2%#2 | 52.1%#2 | -271.0%#4 | -12.9%#3 | — | — | 54.1%#4 | — |
| ABVC | $40M#13 | — | 3.7x#8 | 134.0x#8 | 48.0%#3 | -61.3%#9 | -2416.0%#8 | -73.4%#8 | -65.9%#6 | — | -67.5%#14 | — |
| ABVX | $11.1B#3 | — | — | — | — | — | — | — | — | — | 1600.6%#1 | — |
| ACAD | $4.5B#5 | 11.9x#3 | 3.6x#7 | 4.2x#2 | 11.9%#4 | 73.0%#1 | 9.8%#3 | 31.3%#1 | 10.9%#2 | — | 22.3%#7 | — |
| ACET | $84M#12 | — | 0.6x#1 | — | — | 0.3%#6 | — | -83.4%#9 | — | — | -20.9%#9 | — |
| ACIU | $262M#10 | — | — | — | — | — | — | — | — | — | 24.6%#6 | — |
| ACRS | $797M#8 | — | 5.6x#10 | 101.9x#7 | -58.2%#7 | 50.8%#3 | -975.9%#6 | -45.2%#5 | -60.8%#5 | 3#1 | 272.0%#2 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议